On Friday December 12, 2025, researchers from the Japanese corporation of Bristol Myers Squibb (BMS) visited our Center.

BMS is a core company that develops and markets Opdivo (nivolumab), one of the world’s first-generation PD-1 inhibitors, which blocks the function of PD-1 discovered by Tasuku Honjo, the Director of our Center. BMS has also made a generous donation toward the construction of our Center’s research building.
https://www.ccii.med.kyoto-u.ac.jp/en/2021/01/26/start-of-the-construction-of-the-bms-building/

The purpose of the visit is to engage in an initiative similar to employee training within the company’s medical division, where researchers are devoted to identifying challenges that current treatment approaches cannot yet fully address and to developing solutions through their daily research efforts.

Following lectures by Associate Professor Takahashi and Associate Professor Murakami. Associate Professor Sugiura provided explanations of the latest equipment. The BMS team commented that the training was highly informative and rewarding.

For our Center, this was also an excellent opportunity to help them deepen their understanding of the center. We hope to continue to strengthen our collaborative relationship in the future. We look forward to deepening the collaborative relationship between our two organizations in the future.